Founded in 2013 and headquartered in Hangzhou, Kaibao Bio has developed the only early-stage lung cancer blood screening product in China that has been validated by a large sample of evidence-based medicine. The company's product has received recognition, winning the second prize of the National Technology Progress Award. It has also completed the quotation of medical products in 19 provinces/cities and has been included in the medical insurance system of 3 provinces/cities.